5 assets in Metachromatic Leukodystrophy

Therapeutic assets addressing Metachromatic Leukodystrophy, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Busulfanum Metachromatic Leukodystrophy	Masonic Cancer Center, University of Minnesota	P2/3	BB (67)
Anti-Human T-Lymphocyte Immunoglobulin, Rabbit Metachromatic Leukodystrophy	Masonic Cancer Center, University of Minnesota	P2/3	B (62)
Alemtuzumab Metachromatic Leukodystrophy	Masonic Cancer Center, University of Minnesota	P2	B (57)
Cald Hr-D Metachromatic Leukodystrophy	Masonic Cancer Center, University of Minnesota	P2	CCC (53)
Duoc-01 Metachromatic Leukodystrophy	Joanne Kurtzberg, MD	P1	CC (43)